B+
Bull case
25%
Probability
Target price
$14.39
+65.4% vs current
HLN
HaleonCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$11.39
+30.9% vs current
B-
Bear case
15%
Probability
Target price
$8.99
+3.3% vs current
AI sentiment snapshot
Latest data as of 2026-02-06
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+84.8
Score
AI commentary
- Median target near $11.39 implies modest upside from the anchor [#SERP-3]. - Target dispersion shows mixed analyst conviction and range risk [#SERP-1]. - Near-term moves tied to quarterlies and consensus updates; long-term re-rating depends on execution of cost and product plans [#SERP-6].
RankAlpha Sentiment AI - 2026-02-06
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-03-31eventAnalyst re-rating following quarterly/annual resultsHigh impact
Results and guidance release may reset analyst 12‑month targets; if revenue mix or margin trends diverge from consensus this could move targets materially (assumed window end used) [#SERP-1], [#SERP-6].
2026-05-07catalystNear-term sales/earnings updateHigh impact
Market watches upcoming operational updates and any FY2025 earnings commentary; modest upside if organic growth accelerates or cost initiatives beat market expectations [#SERP-3]. Assumed date used for short horizon projection.
2027-02-06catalystExecution of cost and innovation pipelineHigh impact
Multi-year payoff from margin improvement and new product launches could re-rate consumer-health multiples; long horizon outcome depends on sustained SKU performance and market share gains [#SERP-7].
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-06 • Updated nightlySource: Internal modelMethodology